| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | RP35; SEMB; SEMAB; CORD10 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SEMA4A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SEMA4A抗体的3篇参考文献及其摘要概括：
1. **文献名称**: *SEMA4A inhibits angiogenesis in experimental autoimmune uveitis through suppression of VEGF receptor 2*
**作者**: Liu H, et al.
**摘要**: 该研究发现SEMA4A抗体通过阻断VEGFR2信号通路抑制血管生成，揭示了SEMA4A在自身免疫性葡萄膜炎中的抗血管生成作用，为治疗炎症性眼病提供新靶点。
2. **文献名称**: *SEMA4A promotes T helper 1 cell response in autoimmune neuroinflammation via CD86-dependent antigen presentation*
**作者**: Okuno T, et al.
**摘要**: 研究利用SEMA4A抗体阻断实验，证明SEMA4A通过增强抗原呈递细胞表面的CD86表达，促进Th1细胞分化，加剧多发性硬化症模型中的神经炎症反应。
3. **文献名称**: *SEMA4A as a novel biomarker and therapeutic target in colorectal cancer*
**作者**: Zhang Y, et al.
**摘要**: 该研究通过SEMA4A抗体检测发现，SEMA4A在结直肠癌组织中高表达，且与肿瘤血管生成和转移相关，提示其可作为预后标志物及抗血管治疗潜在靶点。
以上文献均聚焦SEMA4A抗体在疾病机制研究和治疗应用中的价值，涵盖免疫调节、肿瘤微环境等领域。
The SEMA4A antibody targets Semaphorin-4A (SEMA4A), a transmembrane glycoprotein belonging to the semaphorin family, which plays critical roles in axonal guidance, immune regulation, and vascular development. SEMA4A interacts with receptors like Plexin B and Tim-2. modulating signaling pathways involved in cell migration, adhesion, and immune response. In the immune system, SEMA4A regulates T-cell activation, dendritic cell function, and Th1/Th17 differentiation, linking it to autoimmune and inflammatory diseases. Dysregulation of SEMA4A has been implicated in pathologies such as cancer, multiple sclerosis, rheumatoid arthritis, and allergic disorders, where it may promote angiogenesis, metastasis, or immune dysregulation.
Antibodies against SEMA4A are primarily used as research tools to study its biological functions and therapeutic potential. Monoclonal antibodies blocking SEMA4A or its receptors have shown promise in preclinical models, attenuating autoimmune inflammation or inhibiting tumor growth by disrupting pro-angiogenic or immunosuppressive signals. However, the dual roles of SEMA4A in immune homeostasis and disease complicate therapeutic targeting, necessitating context-specific approaches. Current research focuses on clarifying its mechanisms in different microenvironments and optimizing antibody-based strategies for clinical translation.
×
